Latesha Elopre
Infectious Disease · Birmingham, ALNPI 1992949135
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,822 of the $16,968 with a category attached, or 75.6%. Viiv Healthcare Company accounts for 62.5% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $14,265, more than ten times the $651 reported in 2021.
Across 26 payments — averaging $652.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$11K
- Gilead$4K
- Roche Diagnostics Corporation$1K
- Merck$994
- Janssen Scientific Affairs, LLC$651
Across 3 payments — averaging $24,304 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$73K
What the payments were for
- Royalty or licence$871%
- Consulting fees$12,82276%
- Speaking & faculty fees$1,0586%
- Grants$5643%
- Travel & lodging$1,92611%
- Food & beverage$5103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 11 | $10,612 |
| Gilead | 6 | $3,653 |
| Roche Diagnostics Corporation | 1 | $1,058 |
| Merck | 6 | $994 |
| Janssen Scientific Affairs, LLC | 2 | $651 |
How this compares
$16,968 in reported general payments places this provider in the 80th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 52 | $207,280 |
| JulucaDolutegravir/Rilpivirine | 21 | $69,791 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $31,590 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $28,721 |
| Amlodipine Besylate | 33 | $142 |
| Rosuvastatin Calcium | 17 | $60 |
| Atorvastatin Calcium | 21 | $57 |
| Chlorthalidone | 11 | $45 |
| Carvedilol | 14 | $39 |
| Lisinopril | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,653 | $236,00166 claims |
| Viiv Healthcare CompanyJuluca, Dovato | $10,612 | $101,38233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Birmingham
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
- Peter PappasBirmingham$25K
- Jeanne MarrazzoBirmingham$23K
- Todd McCartyBirmingham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.